About
Sandy Shultz is a Professor and Group Leader in the Department of Neuroscience within the School of Translational Medicine at Monash University, based at the Van Cleef Centre for Nervous Diseases. His research is dedicated to understanding traumatic brain injury (TBI), concussion, and post-traumatic epilepsy, with a strong emphasis on pathophysiological mechanisms, biomarker discovery, and therapeutic development.
His research interests center on traumatic brain injury, neuroinflammation, biomarkers, and translational neuroscience. He employs both preclinical rodent models and clinical studies to investigate the neurological consequences of trauma, including intimate partner violence-related brain injury and perinatal trauma. His work integrates neuroimaging, molecular biology, and behavioral analysis to uncover mechanisms and potential treatments.
The recent articles highlight a consistent focus on TBI and its complications, including the impact of infections like Toxoplasma gondii on brain injury outcomes, structural brain changes in chronic TBI, and the development of diagnostic and rehabilitation strategies for concussion. These publications reflect a multidisciplinary approach spanning molecular, systems, and clinical neuroscience.
He has received the Brain Foundation 2019 Research Gift for his contributions to neuroscience research.
Sandy Shultz is actively involved in major research projects such as the SELECT Trial (sodium selenate for epilepsy), INFORMED (concussion management in sports), and NIH-funded initiatives on epilepsy therapy and biomarker discovery. These projects involve extensive collaboration with national and international researchers and institutions, underscoring his leadership in the field.
He leads the Shultz Lab, a dynamic research group focused on advancing the understanding and treatment of nervous system injuries. The lab engages in both fundamental and applied research, contributing significantly to the field of translational medicine.
